Amarin Corporation plc provides preliminary revenue guidance for the fourth quarter and full year of 2017 and first quarter and second quarter of 2018. For the fourth quarter, the company estimated net revenues of $51 million to $54 million.

For the full year 2017, the company estimated net product revenue to have reached between $177 million and $180 million. These results are estimated to have exceeded the upper end of the company's previously reported guidance for 2017 net product revenue and represent an increase of approximately $48 million to $51 million (approximately 37% to 40%) over full year 2016 results. Both full year and fourth quarter 2017 net revenue growth were driven by increased prescriptions for Vascepa® (icosapent ethyl) capsules.

For the first quarter of 2018, net product revenue will be between $45 and $48 million, representing significant growth over the same period in the prior year.

For the second quarter of 2018, the company anticipates results will rebound with net product revenue anticipated in second quarter of 2018 of $55 million or more.